Can you take Keytruda with Tarlatamab?

The pembrolizumab in Keytruda has a moderate potential interaction with Autoimmune Disorders.

Pembrolizumab and berahyaluronidase alfa-pembrolizumab can cause immune-mediated adverse reactions, which may be severe or fatal. Immune-mediated adverse reactions can occur in any organ system or tissue, can affect more than 1 body system simultaneously, and can occur at any time after starting therapy. This may be considered when using pembrolizumab in patients with immune system disorders (e.g., ulcerative colitis, Crohn's disease, lupus) or with conditions affecting the nervous system (e.g., myasthenia gravis, Guillain-Barre syndrome). It is recommended to monitor patients closely for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.

The pembrolizumab in Keytruda has a moderate potential interaction with Bone Marrow Transplantation.

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

The pembrolizumab in Keytruda has a moderate potential interaction with History, Radiation Therapy.

Pembrolizumab and berahyaluronidase alfa-pembrolizumab can cause immune-mediated pneumonitis; fatal cases have been reported. In general, the incidence of pneumonitis was higher in patients with prior thoracic radiation. This may be considered when using either drug in patients who have received thoracic radiation.

The pembrolizumab in Keytruda has a moderate potential interaction with Infectious Gastroenteritis.

Pembrolizumab and berahyaluronidase alfa-pembrolizumab can cause immune-mediated colitis, which may present with diarrhea. CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to exclude alternative etiologies.

The pembrolizumab in Keytruda has a moderate potential interaction with Inflammatory Bowel Disease.

Pembrolizumab and berahyaluronidase alfa-pembrolizumab can cause immune-mediated colitis, which may present with diarrhea. CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to exclude alternative etiologies.

The pembrolizumab in Keytruda has a moderate potential interaction with Liver Disease.

The effect of severe liver dysfunction (total bilirubin greater than 3 times the upper limit of normal and any AST) on the pharmacokinetics of pembrolizumab is unknown.

Tarlatamab has a moderate potential interaction with Liver Disease.

The effects of moderate to severe hepatic impairment on the pharmacokinetics of tarlatamab are unknown.

The pembrolizumab in Keytruda has a moderate potential interaction with Multiple Myeloma.

The use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies in combination with a thalidomide analog plus dexamethasone is not recommended in patients with multiple myeloma outside of controlled trials. In randomized clinical trials in patients with multiple myeloma, the addition of a PD-1/PD-L1 blocking antibody to a thalidomide analog plus dexamethasone (a use for which no PD-1 or PD-L1 blocking antibody is indicated) resulted in increased mortality.

The pembrolizumab in Keytruda has a moderate potential interaction with Organ Transplant.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. This may be considered when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Tarlatamab has a moderate potential interaction with Renal Dysfunction.

The effects of severe renal impairment (eGFR 15 to 29 mL/min) and end-stage renal disease (eGFR less than 15 mL/min) on the pharmacokinetics of tarlatamab are unknown.